DrugPatentWatch Database Preview
Daiichi Sankyo Company Profile
What is the competitive landscape for DAIICHI SANKYO, and when can generic versions of DAIICHI SANKYO drugs launch?
DAIICHI SANKYO has eleven approved drugs.
There are four US patents protecting DAIICHI SANKYO drugs.
There are one hundred and sixty-five patent family members on DAIICHI SANKYO drugs in thirty-two countries and forty-one supplementary protection certificates in eleven countries.
Summary for Daiichi Sankyo
| International Patents: | 165 |
| US Patents: | 4 |
| Tradenames: | 9 |
| Ingredients: | 9 |
| NDAs: | 11 |
| Patent Litigation for Daiichi Sankyo: | See patent lawsuits for Daiichi Sankyo |
| PTAB Cases with Daiichi Sankyo as patent owner: | See PTAB cases with Daiichi Sankyo as patent owner |
Drugs and US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Daiichi Sankyo Inc | ROXYBOND | oxycodone hydrochloride | TABLET;ORAL | 209777-001 | Apr 20, 2017 | RX | No | No | 7,955,619 | ➤ Sign Up | Y | ➤ Sign Up | |||
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-001 | Oct 2, 2009 | RX | Yes | No | 7,229,613*PED | ➤ Sign Up | Y | ➤ Sign Up | |||
| Daiichi Sankyo | BENICAR HCT | hydrochlorothiazide; olmesartan medoxomil | TABLET;ORAL | 021532-002 | Jun 5, 2003 | AB | RX | Yes | No | ➤ Sign Up | ➤ Sign Up | ||||
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
Expired US Patents for Daiichi Sankyo
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | TABLET;ORAL | 021176-001 | May 26, 2000 | 6,784,254*PED | ➤ Sign Up |
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | FOR SUSPENSION;ORAL | 022362-002 | Oct 2, 2009 | 7,101,960*PED | ➤ Sign Up |
| Daiichi Sankyo | WELCHOL | colesevelam hydrochloride | CAPSULE;ORAL | 021141-001 | May 26, 2000 | 5,919,832*PED | ➤ Sign Up |
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
Paragraph IV (Patent) Challenges for DAIICHI SANKYO drugs
| Drugname | Dosage | Strength | Tradename | Submissiondate |
|---|---|---|---|---|
| ➤ Subscribe | Tablets | 625 mg | ➤ Subscribe | 2009-07-01 |
| ➤ Subscribe | Tablets | 5 mg/20 mg and 10 mg/40 mg | ➤ Subscribe | 2008-02-11 |
| ➤ Subscribe | Tablets | 5 mg, 20 mg and 40 mg | ➤ Subscribe | 2006-04-25 |
| ➤ Subscribe | Tablets | 40 mg/12.5 mg and 40 mg/25 mL | ➤ Subscribe | 2007-02-15 |
| ➤ Subscribe | Powder for Oral Suspension | 1.875 g/Packet and 3.75 g/Packet | ➤ Subscribe | 2010-04-09 |
| ➤ Subscribe | Tablets | 10 mg/20 mg and 5 mg/40 mg | ➤ Subscribe | 2008-03-31 |
| ➤ Subscribe | Tablets | 20 mg/12.5 mg | ➤ Subscribe | 2007-05-11 |
| ➤ Subscribe | Capsules | 30 mg | ➤ Subscribe | 2009-02-27 |
Non-Orange Book US Patents for Daiichi Sankyo
For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.
The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.
| Patent No. | Title | Estimated Patent Expiration |
|---|---|---|
| 7,261,880 | Methods of treating Syndrome X with aliphatic polyamines | ➤ Sign Up |
| 8,377,428 | Low salt forms of polyallylamine | ➤ Sign Up |
| 7,541,024 | Low salt forms of polyallylamine | ➤ Sign Up |
| Patent No. | Title | Estimated Patent Expiration |
International Patents for Daiichi Sankyo Drugs
Supplementary Protection Certificates for Daiichi Sankyo Drugs
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
|---|---|---|---|
| C0009 | Belgium | ➤ Sign Up | PRODUCT NAME: IRBESARTAN / HYDROCHLOROTHIAZIDE; REGISTRATION NO/DATE: EU/1/98/086/001 19981015 |
| 0443983/03 | Switzerland | ➤ Sign Up | PRODUCT NAME: VALSARTAN + AMLODIPINE + HYDROCHLOROTHIAZIDE; REGISTRATION NUMBER/DATE: SWISSMEDIC 59407 16.09.2009 |
| C/GB03/024 | United Kingdom | ➤ Sign Up | PRODUCT NAME: OLMESARTAN MEDOXOMIL, OPTIONALLY IN THE FORM OF A PHAMACEUTICALLY ACCEPTABLE SALT; REGISTERED: DE 50202.00.00 20020813; DE 50202.01.00 20020813; DE 50202.02.00 20020813; DE 50205.00.00 20020813; DE 50205.01.00 20020813; DE 50205.02.00 20020813; UK PL 08265/0015 20030522; UK PL 08265/0016 20030522; UK PL08265/0017 20030522 |
| Supplementary Protection Certificate | SPC Country | SPC Expiration | SPC Description |
Similar Applicant Names
Here is a list of applicants with similar names.
